These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 32296003)
41. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210 [TBL] [Abstract][Full Text] [Related]
42. Parotid acinar cell carcinoma in a long-term survivor of childhood acute lymphoblastic leukemia. Cheuk DK; Shek TW; Chan GC; Lau YL; Ha SY; Chiang AK Pediatr Blood Cancer; 2008 Mar; 50(3):636-9. PubMed ID: 16865683 [TBL] [Abstract][Full Text] [Related]
43. [Results and suggestion from comparing between world excellent protocols of childhood acute lymphoblastic leukemia]. Fu RY; Liao QK; Jia CS Zhonghua Er Ke Za Zhi; 2003 Jul; 41(7):515-9. PubMed ID: 14746678 [No Abstract] [Full Text] [Related]
44. Myocardial ischemia in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. Saviola A; Luppi M; Potenza L; Morselli M; Bresciani P; Ferrari A; Riva G; Torelli G Eur J Haematol; 2004 Jan; 72(1):71-2. PubMed ID: 14962268 [TBL] [Abstract][Full Text] [Related]
45. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659 [TBL] [Abstract][Full Text] [Related]
46. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Gugliotta L; Mazzucconi MG; Leone G; Mattioli-Belmonte M; Defazio D; Annino L; Tura S; Mandelli F Eur J Haematol; 1992 Aug; 49(2):63-6. PubMed ID: 1397242 [TBL] [Abstract][Full Text] [Related]
47. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol. Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691 [TBL] [Abstract][Full Text] [Related]
48. Half-and-half nails in a pediatric patient after chemotherapy. Afsar FS; Ozek G; Vergin C Cutan Ocul Toxicol; 2015; 34(4):350-1. PubMed ID: 25597374 [TBL] [Abstract][Full Text] [Related]
49. Avascular necrosis--an antineoplastic-treatment-related toxicity: the experiences of two institutions. Sawicka-Zukowska M; Kajdas L; Muszynska-Roslan K; Krawczuk-Rybak M; Sonta-Jakimczyk D; Szczepanski T Pediatr Hematol Oncol; 2006 Dec; 23(8):625-9. PubMed ID: 17065138 [TBL] [Abstract][Full Text] [Related]
50. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood. Pillon M; Aricò M; Basso G; Locatelli F; Citterio M; Micalizzi C; Testi AM; Barisone E; Nardi M; Lombardi A; Rondelli R; Rosolen A; Pediatr Blood Cancer; 2011 Apr; 56(4):544-50. PubMed ID: 21298738 [TBL] [Abstract][Full Text] [Related]
51. Characterization of hypertriglyceridemia induced by L-asparaginase therapy for acute lymphoblastic leukemia and malignant lymphoma. Tozuka M; Yamauchi K; Hidaka H; Nakabayashi T; Okumura N; Katsuyama T Ann Clin Lab Sci; 1997; 27(5):351-7. PubMed ID: 9303174 [TBL] [Abstract][Full Text] [Related]
52. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group. Liang DC; Hung IJ; Yang CP; Lin KH; Chen JS; Hsiao TC; Chang TT; Pui CH; Lee CH; Lin KS Leukemia; 1999 Feb; 13(2):155-60. PubMed ID: 10025887 [TBL] [Abstract][Full Text] [Related]
53. Outcomes of pediatric mixed phenotype acute leukemia treated with lymphoid directed therapy: Analysis of an institutional series from India. Seetharam S; Thankamony P; Gopakumar KG; Nair RA; Jacob PM; Jagathnath Krishna KM; Rajeswari B; Nair M; Guruprasad CS; Prasanth VR Pediatr Hematol Oncol; 2021 May; 38(4):358-366. PubMed ID: 33635170 [TBL] [Abstract][Full Text] [Related]
54. Treatment of high-risk acute lymphoblastic leukemia with protocols PETHEMA LAL 7/78 and LAL 17/84. Ortega JJ; Javier G; Olivé T An Esp Pediatr; 1988 Oct; 29 Suppl 34():72-83. PubMed ID: 3214043 [No Abstract] [Full Text] [Related]
55. The analysis of correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol. Mihal V; Hajduch M; Noskova V; Janostakova A; Safarova M; Orel M; Kouzmina G; Stary J; Blazek B; Pospisilova D Bull Cancer; 2004 Apr; 91(4):E80-9. PubMed ID: 15562558 [TBL] [Abstract][Full Text] [Related]
56. [L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia]. Konya H; Tamura S; Miyazaki E; Inoue N; Okamoto T; Takemoto Y; Kohsaki M; Kanemaru A; Kakishita E Rinsho Ketsueki; 1991 Mar; 32(3):250-4. PubMed ID: 2041167 [TBL] [Abstract][Full Text] [Related]
57. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134 [TBL] [Abstract][Full Text] [Related]
58. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Larson RA; Fretzin MH; Dodge RK; Schiffer CA Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262 [TBL] [Abstract][Full Text] [Related]
59. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718 [TBL] [Abstract][Full Text] [Related]
60. Changes in the oral health of children during treatment for acute lymphoblastic leukaemia. O'Sullivan EA; Duggal MS; Bailey CC Int J Paediatr Dent; 1994 Mar; 4(1):31-4. PubMed ID: 7748846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]